Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Preferred Shares Repurchased Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Vivos Therapeutics (VVOS) Long-Term Debt Repayments (2021)

Vivos Therapeutics has reported Long-Term Debt Repayments over the past 1 years, most recently at $25000.0 for Q1 2021.

Quarterly Long-Term Debt Repayments changed N/A to $25000.0 in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $25000.0 through Dec 2021, changed N/A year-over-year, with the annual reading at $25000.0 for FY2021, 66.67% down from the prior year.
Long-Term Debt Repayments was $25000.0 for Q1 2021 at Vivos Therapeutics.
Over five years, Long-Term Debt Repayments peaked at $25000.0 in Q1 2021 and troughed at $25000.0 in Q1 2021.